Get the Stockscreener App
1.87
7.47%
0.13
Tscan Therapeutics Inc stock is traded at $1.87, with a volume of 353.25K.
It is up +7.47% in the last 24 hours and up +1.08% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.74
Open:
$1.75
24h Volume:
353.25K
Relative Volume:
0.65
Market Cap:
$98.12M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.0447
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+3.89%
1M Performance:
+1.08%
6M Performance:
-13.82%
1Y Performance:
-67.14%
1-Day Range:
$1.75
$1.89
1-Week Range:
$1.63
$1.89
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.87 | 101.58M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Does TScan Therapeutics Inc. fit your quant trading modelJuly 2025 Closing Moves & Technical Pattern Recognition Alerts - Newser
TScan Therapeutics Inc. recovery potential after sell offQuarterly Profit Report & Technical Entry and Exit Tips - Newser
Statistical indicators supporting TScan Therapeutics Inc.’s strengthJuly 2025 Institutional & Expert Approved Trade Ideas - Newser
Combining machine learning predictions for TScan Therapeutics Inc.July 2025 Earnings & Smart Investment Allocation Insights - Newser
Real time scanner hits for TScan Therapeutics Inc. explainedWeekly Investment Summary & Expert Approved Trade Ideas - Newser
Visualizing TScan Therapeutics Inc. stock with heatmapsJuly 2025 Short Interest & Weekly Breakout Watchlists - Newser
Volatility clustering patterns for TScan Therapeutics Inc.Quarterly Market Summary & Free High Return Stock Watch Alerts - Newser
Order flow analysis tools used on TScan Therapeutics Inc.Market Movement Recap & High Accuracy Buy Signal Tips - Newser
TScan Therapeutics Inc. stock trend forecastPortfolio Performance Summary & Stepwise Swing Trade Plans - Newser
Sector ETF performance correlation with TScan Therapeutics Inc.Volume Spike & Community Trade Idea Sharing - Newser
How high can TScan Therapeutics Inc. stock go2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
What moving averages say about TScan Therapeutics Inc.2025 Major Catalysts & Technical Entry and Exit Tips - Newser
What is Lifesci Capital’s Forecast for TCRX FY2025 Earnings? - Defense World
Full technical analysis of TScan Therapeutics Inc. stockWall Street Watch & Risk Adjusted Buy/Sell Alerts - Newser
Identifying reversal signals in TScan Therapeutics Inc.2025 Market Trends & Technical Buy Zone Confirmation - Newser
HC Wainwright Expects Higher Earnings for TScan Therapeutics - Defense World
Detecting price anomalies in TScan Therapeutics Inc. with AIJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
What recovery options are there for TScan Therapeutics Inc.Portfolio Growth Summary & Stock Timing and Entry Methods - Newser
TScan Therapeutics Inc. Shows Support at Fibonacci LevelWatch List & Technical Entry and Exit Alerts - 선데이타임즈
What are analysts’ price targets for TScan Therapeutics Inc.2025 Winners & Losers & Real-Time Volume Analysis - mustnews.co.kr
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Measuring TScan Therapeutics Inc.’s beta against major indices2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
What machine learning models say about TScan Therapeutics Inc.Layoff News & Smart Swing Trading Techniques - Newser
What Fibonacci levels say about TScan Therapeutics Inc. reboundJuly 2025 News Drivers & Weekly High Return Stock Forecasts - Newser
Equities Analysts Offer Predictions for TCRX Q3 Earnings - Defense World
Intrinsic Value of TScan Therapeutics Inc. Stock: Is It Undervalued or OvervaluedMarket Performance Recap & Low Risk Growth Stock Ideas - Newser
Should you hold or exit TScan Therapeutics Inc. now2025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - Newser
TScan Therapeutics Inc. Breakout Confirmed by Volume MetricsJuly 2025 Review & Stepwise Entry/Exit Trade Alerts - 선데이타임즈
What makes TScan Therapeutics Inc. stock price move sharplyGold Moves & Free Technical Pattern Based Buy Signals - thegnnews.com
Is TScan Therapeutics Inc. a momentum stockDip Buying & Low Risk Entry Point Guides - thegnnews.com
TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely - Yahoo Finance
TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating - TipRanks
Evaluating TScan Therapeutics Inc. with trendline analysisWeekly Trade Summary & Growth-Oriented Investment Plans - Newser
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):